What are ASCO recommendations for second-line therapy of stage IV non–small cell lung cancer (NSCLC) in patients with ROS1 rearrangement?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with ROS1 rearrangement, recommendations include the following:

  • Single-agent crizotinib, if first-line therapy did not include crizotinib
  • Platinum-based therapy with or without bevacizumab, if first-line therapy included crizotinib

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!